Transgene to Present Preclinical Data on Novel Oncolytic Virus at SITC 2026 Supporting its Potential for Systemic Delivery
03/11/2026 17:45Informations privilégiéesInformations réglementées continues
AMFPublicação imediata
Preclinical data support the potential of PoxSTG-EEV to overcome key barriers to systemic (IV) delivery and enhance tumor dissemination of oncolytic viruses
Transgene to Present Preclinical Data on Novel Oncolytic Virus at SITC 2026
Supporting its Potential for Systemic Delivery
Preclinical data support the potential of PoxSTG-EEV to overcome key barriers to systemic (IV) delivery and enhance tumor dissemination of oncolytic viruses
Strasbourg, France, November 3, 2026, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that new preclinical data on PoxSTG-EEV, its novel enveloped chimeric oncolytic virus, have been selected for a poster presentation at the Society for
Immunotherapy of Cancer (SITC) 2026 Annual Meeting.
SITC will take place November 4 - 8, 2026, in Phoenix, Arizona (USA).
These data highlight the potential of PoxSTG-EEV, a next-generation chimeric oncolytic virus with a novel Extracellular Enveloped Virion (EEV) formulation developed by Transgene to enhance intratumoral dissemination and increase resistance to immune-mediated neutralization, supporting its potential for systemic (IV) administration.
"Oncolytic viruses have shown considerable promise in cancer treatment, however their full therapeutic potential could be further enhanced by improvements related to systemic delivery and intratumoral spread," said Katell Bidet-Huang, Chief Scientific Officer ad interim at Transgene. "These preclinical findings demonstrate the potential of PoxSTG-EEV to address some of these barriers and highlight the continued innovation from Transgene’s viral vector expertise."
"PoxSTG-EEV combines the PoxSTG chimeric viral vector backbone, with an EEV-enriched formulation designed to generate and preserve the EEV form of the virus and serves as the backbone for Transgene’s proprietary EEVOLVTM platform, supporting the development of a new generation of poxvirus-based-clinical candidates” added Johann Foloppe, PhD, Senior scientist and Project leader at Transgene.
Preclinical studies showed that compared with conventional oncolytic vaccinia viruses, PoxSTG- EEV enhanced cytotoxic activity across multiple tumor cell lines and intratumoral dissemination, while maintaining infectivity in the presence of active complement and neutralizing antibodies. In mouse models, intravenous administration significantly reduced tumor growth and prolonged survival.
P R E S S R E L E A S E
Poster Details
Title: “PoxSTG-EEV: a Novel Enveloped Virion – Based Formulation of a Chimeric Oncolytic
PoxVirus Adapted for Systemic Delivery”